Yes. Thank you very much. And welcome everybody to BioInvent's Q3 presentation and report. I will start the presentation. I am Martin Welsch, the CEO. I would like to start with the events in the third quarter. So BI-1808, which is our leading value driver, has gotten a lot of attention. We received FDA Fast Track Designation for the treatment of recurrent ovarian cancer. And then, we had an abstract from modest to meaningful in platinum-resistant ovarian cancer that was accepted for poster presentation at ESMO. I think we will return to the data in more detail. And then we also published two scientific papers in peer-reviewed journals. One was in Cancer Research that was highlighting the mode of action. And then we had another publication just a little bit more than a week ago. But I will come back to that later, but there was one presentation in the third quarter that specifically highlighted FcγRIIB and our BI-1206 program. So then, events after the end of the period. So the board of directors, as we announced yesterday evening, has decided to carry out a rights issue of approximately SEK 430 million, which is gross before issue costs, of which SEK 350 million is covered by subscription commitments and guarantee undertakings. And of course, this is still subject to approval at the extraordinary general meeting, for which we also called yesterday evening. We will adjust the organization to support the prioritized clinical programs. First, BI-1808. Number 2, BI-1206, and I will come back to that later throughout my presentation. BI-1808 and KEYTRUDA, we have shown the latest data at ESMO. They induce durable responses in heavily pretreated platinum-resistant ovarian cancer. And the poster was granted the best poster award in the investigational immunotherapy section. And basically the data is repeating what we have shown at ASCO, but just in a higher number of patients. Then we had to announce that Stefan Ericsson, our CFO, will retire in 2027. Stefan has been with the company for roughly 30 years. He is going into his well-deserved retirement. But we will do that in a very structured way so that there will be no loose ends. Stefan has also agreed to support and help us in this transition. And that was what I mentioned on the first slide. We had first-in-human BI-1808 data published in Clinical Cancer Research just over a week ago. So basically two presentations, two publications covering BI-1808, which is a completely new and unique mode of action. And we are actually the first ones developing this mode of action. So a little bit more details regarding the financing and the organization, as already mentioned, we have considered all options and, in the end, decided to proceed with this rights issue. And we might discuss that also in more detail during the Q&A section. That is targeting SEK 430 million. This is gross before issue costs. As I mentioned previously, SEK 350 million will be covered by subscription commitments and guarantee undertakings. And of course, this has to be approved during an EGM, which will happen on December 1st.
As I already mentioned in my introduction.
So the organization also will be adjusted. We are considering a workforce reduction of up to 20 FTEs, while maintaining our focus on BI-1808 as our top priority and BI-1206 as our second, and I have already mentioned Stefan Ericsson's retirement. And then I think also something that is really interesting. Dharminder Chahal has been nominated to return as a board member. Of course, this is also subject to approval at the AGM and clearly shows the very strong support that we have from Van Herk, then a little bit more on the data.
So this slide summarizes the data that we have just shown at ESMO. As I said earlier, it is a repeat of the data, but with a higher number of patients. So a very nice, strong objective response with one complete response and seven partial responses, along with a nice disease control rate of 53%. And several patients are stable. More than ten months. Six patients are still on treatment at the cutoff in September. We had less than 5% treatment-related discontinuation out of 81 solid tumor patients, which I think is very important because with most of the other modern treatments, you have a much higher treatment-related discontinuation, which of course is not good for the patients. What is discussed a lot is the progression-free survival. And you can see the numbers below. So median progression-free survival as per iRECIST is 10.3 months, and that is probably the most fair consideration because RECIST is really made for chemotherapeutic agents or small molecule compounds, but it is still 4.1. And then as a comparison, pembrolizumab alone in the KEYNOTE-100 is 2.1. And also to mention here. So the patient population that we are treating is heavily pretreated platinum-resistant ovarian cancer, with a median of four prior lines, which is a patient population that is very unresponsive; iRECIST captures delayed responses. The 2.1 month figure is from a different study. That is an indirect comparison. And then the duration of response is not bad. The median follow-up is 11.6 months. Overall, it is a strong data set that we presented at ASCO for BI-1808, and we will share a little bit more on the data here. We show a response in a setting where others have previously failed to deliver. When you look at the objective response rate on the left-hand side, you see the combination is 24%, pembrolizumab alone is 8%, and BI-1808 alone is 6%. So you can see that even as a single agent in recurrent ovarian cancer, BI-1808 behaves very much like pembrolizumab. And that is what we have always said. So when we talk to the outside world, we basically say we have the next version of KEYTRUDA, the next new immuno-oncology mechanism on the right hand side. I do not have the time today to go through this in detail, but this is the very good safety profile that we have. And this is actually quite impressive, considering the heavy pretreatment history. Okay, so what are the next steps? First of all, we have FDA Fast Track Designation for BI-1808 in ovarian cancer that was granted in early August 2026. But we have it also for relapsed or refractory mycosis fungoides and Sézary syndrome CTCL. And that reflects the high unmet medical need. We received the best poster award for the ovarian cancer data at ESMO in the investigational immunotherapy section, and the phase one data and MOA were published. I mentioned that already. Clinical Cancer Research published the phase one data and the mechanism of action, which is very positive. And also additional validation. The next step is the phase 1/2a part C, which is about to start in Q1 2027. And there, we will have three randomized arms with 20 patients each. And then. BI-1808 is being tested in two different concentrations: 1000 mg and 500 mg. The control arm will be pembrolizumab combined with weekly paclitaxel, plus or minus bevacizumab. We expect the first data in the second half of 2027. And that should be very interesting. And that is the data that actually corporates as well as large investors are happy to see and want to see. Okay. Then the expected milestones ahead and our focus. In H1 2027, we will start the study that I just mentioned, the part C, which is the most important value inflection point for the company.
Then we will complete the Phase 2a dose optimization for BI-1808 as a monotherapy in CTCL. I would also like to remind everybody. So, this is obviously another strong validator of BI-1808. The data that we have actually positions BI-1808 in the front line as a single agent to treat CTCL. And then last but not least, we are also waiting for the first readout of BI-1206 plus KEYTRUDA in first-line non-small cell lung cancer (NSCLC) and uveal melanoma. Then, during the second half of next year, we expect the first data from the BI-1808 triplet study in ovarian cancer, followed by a potential start of the BI-1206 phase 2b trial, pending data and partnering. We have a clear goal and have now engaged with an external party to help us push potential partnering around BI-1206, but also initiate discussions around 1808. BI-1808. So the focus is very clear. So two targets are TNFR2 and FcγRIIB. And also to highlight this again. So those are first-in-class targets. We are the ones developing those targets in oncology at the moment. And that is always a little bit more difficult because you do not have anything that you can get guidance from. BI-1808 is the current priority. And with the planned rights issue, we aim to take BI-1808 into these randomized and potentially pivotal studies while continuing to develop. BI-1206 with a partner. I think I hand over from here to Stefan, and I will just flip to the next slide. Go ahead, Stefan.